Inflection Point For Regen Med Lauded At London ARM Meeting
Insights from the Alliance for Regenerative Medicine's fifth annual EU Advanced Therapies Investor Day, held in London in November 2017.
You may also be interested in...
Since becoming CEO of TxCell two years ago, Stéphane Boissel has reorganized the R&D plan, restructured and reduced the head count and put the company on the road to scalable manufacturing of CAR-T regulatory cells. And he has put strategic partnerships on the agenda. It is a big change from the situation 12 months ago, he told In Vivo during the Annual European Advanced Therapies Investor Day.
Cell and gene therapies that have the potential to cure require new approaches to value assessment, payment and financing. In the second of a series, the Alliance for Regenerative Medicine identifies potential payment models, highlights key stakeholder concerns and identifies the barriers that must be addressed to enable their integration across the health care system.
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.